ANI Pharmaceuticals ANIP Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $92.15M+17.6% | $78.34M+93.1% | $40.57M+497% | -$10.21M+51.5% | -$21.05M-13.6% | ||
| $89.45M-2.2% | $91.42M0.0% | $91.4M+8.1% | $84.52M+11.3% | $75.94M+12.1% | ||
| $39.25M+3.5% | $37.93M+7.7% | $35.22M+6.7% | $33.02M+5.6% | $31.28M+6.6% | ||
| $208.61M+12.6% | $185.23M+8.5% | $170.72M+22.7% | $139.14M+72.3% | $80.74M+26.1% | ||
| $17.44M+26.0% | $13.84M-7.7% | $14.99M+9.4% | $13.69M-3.1% | $14.13M-13.0% | ||
| -$25.8M+24.8% | -$34.32M+21.3% | -$43.6M+90.0% | -$435.96M-0.6% | -$433.5M-7.1% | ||
| $751K-35.1% | $1.16M-26.0% | $1.56M-3.8% | $1.63M0.0% | $1.63M0.0% | ||
| $21.96M+79.9% | $12.21M+2.5% | $11.92M+3.2% | $11.55M-6.1% | $12.3M+12.2% | ||
| $2.03M— | $0-100% | $297.09M+0.7% | $295.06M+0.4% | $293.78M+0.4% | ||
| —— | —— | —— | $279.38M-0.1% | $279.67M+3.6% | ||
| $161.38M+14.7% | $140.73M+19.6% | $117.63M+628% | -$22.28M+71.7% | -$78.76M-3.3% | ||
| $191.17M+11.5% | $171.39M+10.1% | $155.73M+24.1% | $125.44M+88.3% | $66.61M+39.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does ANI Pharmaceuticals generate?
- ANI Pharmaceuticals (ANIP) generated $208.6M in operating cash flow over the trailing twelve months.
- What is ANI Pharmaceuticals's free cash flow?
- After $17.4M of capital expenditures, ANI Pharmaceuticals's free cash flow was $191.2M over the trailing twelve months, up 187.0% year over year.
- Where does ANI Pharmaceuticals's cash flow data come from?
- Every line is extracted from ANI Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
